ERBB2 and neoplasm: Although NST is associated with the potential for axillary nodal downstaging, the rates of nodal pathologic complete response (pCR) differ substantially by tumor subtype, the rate being higher in human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancers (6–9).